Characteristics and Outcomes of Patients With Primary Central Nervous System Lymphoma: A Single Center Experience and Review of the Literature

Creative Commons License

KORKMAZ S., ŞENCAN M., ÖZÜM Ü., KARADAĞ Ö.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.22, sa.4, ss.227-232, 2012 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 22 Sayı: 4
  • Basım Tarihi: 2012
  • Doi Numarası: 10.4999/uhod.11088
  • Dergi Adı: UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.227-232
  • Sivas Cumhuriyet Üniversitesi Adresli: Evet

Özet

This retrospective study was designed to review the clinicopathological characteristics and outcomes of primary central nervous system lymphoma (PCNSL) cases at our institute. Patients diagnosed with PCNSL at our institute from August 2010 to December 2011 were evaluated. During this period, a total of 5 cases have been diagnosed with PCNSL. Parieto-occipital lobe was the most common site of involvement. Diffuse large B-cell lymphoma (DLBCL) was the most common histological pattern. 4 patients were treated with 3.0 g/m(2) methotrexate (MTX) intravenously concomitant with intraventricular 15 mg MTX and 1 patient was treated with radiotherapy (RT). The median overall survival (OS) was 8 months (minimum: 1 months, maximum: 15 months) and mean OS was 8.4 +/- 5.41 months. As mentioned previous studies, MTX-based chemotherapy regimens are still the most effective treatment option in this patient population.